Medchemfarma has been beneficiary in the call for start-up capital grants for emerging technology companies for the year 2023, through Acció Program (https://accio.gencat.cat) to carry out the Project: New cancer treatments based on covalent kinase inhibitors as immuno-oncological therapies (ACE087/23/000052)
News